U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
This article was originally published in PharmAsia News
Executive Summary
The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions
You may also be interested in...
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
FDA already has conducted such inspections in India since opening an office there.